What Fueled The Previous Growth In The Lewy Body Dementia Treatment Market?
The lewy body dementia treatment market has seen considerable growth due to a variety of factors.
• In recent years, the market size for Lewy body dementia treatment has seen significant growth. Predictions indicate it will expand from $4.43 billion in 2024 to $4.71 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. Various factors have fueled this growth during the historic period, including the offering of supportive care and family education, receiving regulatory approvals and guidelines, the application of multidisciplinary care approaches, and the implementation of psychosocial and behavioral interventions.
What Is The Expected Growth In The Lewy Body Dementia Treatment Market?
The Lewy Body Dementia Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, robust growth is anticipated in the Lewy body dementia treatment market. It is projected to reach a value of $6.17 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%.
The forecast period's growth is largely owing to advances in neurology, targeted research efforts, precision medicine and biomarkers, collaborative healthcare structures, and the broadening of telemedicine. Noteworthy trends for the forecast period comprise supportive measures for families and caregivers, integrated care frameworks, individualized treatment strategies, non-drug interventions, and digital health resolutions.
What Main Forces Are Fueling Expansion In The Lewy Body Dementia Treatment Market?
The growth of the lewy body dementia treatment market is anticipated to be fueled by the increasing instances of brain-related ailments. Disorders affecting the brain, which disrupt its normal functioning, could be mild, moderate, or severe, depending on the degree of brain malformation. Lewy body dementia treatment, which alleviates symptoms such as hallucinations, confusion, and sleepiness by enhancing brain chemicals for improved alertness and cognition effectiveness, is utilized to address these ailments. For example, a report from the American Heart Association Inc., an American-based volunteer charity organization in January 2022, suggested that the number of people suffering from brain disorders in the US is expected to escalate to 9.3 million by 2060. Currently, this number is on the rise in the US. Additionally, one in every six individuals globally is affected by a brain disease. It is projected that by 2021, one billion people globally may be experiencing brain disorders. Hence, the increasing instances of brain-related diseases are amplifying the lewy body dementia treatment market's expansion.
What Are The Primary Segments In The Global Lewy Body Dementia Treatment Market?
The lewy body dementia treatment market covered in this report is segmented –
1) By Drug Type: Antidepressants, Antipsychotic Drugs, Benzodiazepine, Carbidopa-Levodopa, Cholinesterase inhibitors, Modafinil
2) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By Application: Alzheimer’s disease, Dementia, Parkinson’s disease
Subsegments:
1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants
2) By Antipsychotic Drugs, Atypical Antipsychotics: Typical Antipsychotics
3) By Benzodiazepines: Short-acting Benzodiazepines, Long-acting Benzodiazepines
4) By Carbidopa-Levodopa: Immediate-Release Formulations, Extended-Release Formulations
5) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
6) By Modafinil: Standard Formulations, Extended-Release Formulations
Pre-Book The Lewy Body Dementia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Lewy Body Dementia Treatment Market?
One crucial trend gaining traction in the lewy body dementia treatment industry is the focus on product innovation. Key global players in this market are concentrating on creating trailblazing solutions to consolidate their market standing. Take Biogen Inc., an American multinational biotechnology company, for example. In January 2023, Biogen Inc. brought forth a novel medicine called lecanemab. This humanized monoclonal antibody is put to use in the treatment of Alzheimer's disease, a condition linked with Lewy body dementia. The distinctive advantage of lecanemab is its role in decreasing brain amyloid levels. Thereby, it addresses and eliminates the amyloid plaques upon which cognitive deficiencies and dementia in Alzheimer's disease are predicated.
Who Are the Key Players In The Lewy Body Dementia Treatment Market?
Major companies operating in the lewy body dementia treatment market include:
• Mallinckrodt Pharmaceuticals Co.
• BioArctic AB
• Sumitomo Pharma Co. Ltd.
• Jazz Pharmaceuticals Inc.
• Allergan plc
• Novartis International AG
• Pfizer Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH.
• Merck & Co. Inc.
• Biogen Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Bristol Myers Squibb Company
• Calliditas Therapeutics AB
• Chiesi USA Inc.
• GlaxoSmithKline plc
• Eisai Co. Ltd.
• Bausch Health Companies Inc.
• Hisamitsu Pharmaceutical Co. Inc.
• Lundbeck Inc.
What Is The Most Dominant Region In The Lewy Body Dementia Treatment Market?
North America was the largest region in the Lewy body dementia treatment market in 2024. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
